Please find enclosed press release titled as Ind-Swift to make Jammu facility EUGMP and PICS Compliant targets additional revenue of 100 crores from 2029-30 onwards .

Ref: ISLL:CH:2026 Date:18thAugust, 2026 The President The Vice President, Corporate Relationship Department Listing Compliance Department, BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor 25th Floor, Dalal Street, Plot No. C/2, G-Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (E), Mumbai 400 051 BSE Scrip Code: 532305 NSE Symbol: INDSWFTLAB SUBJECT: PRESS RELEASE Respected Sir/Ma’am, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release titled as “Ind-Swift to make Jammu facility EUGMP and PICS Compliant targets additional revenue of 100 crores from 2029-30 onwards.” Kindly take the above information on record. Thanking you, For IND-SWIFT LABORATORIES LTD. PARDEEP VERMA VP-CORPORATE AFFAIRS & COMPANY SECRETARY Encl: a/a PRESS RELEASE IND-SWIFT TO MAKE JAMMU FACILITY EUGMP AND PICS COMPLIANT TARGETS ADDITIONAL REVENUE OF 100 CRORES FROM 2029-30 ONWARDS Ind-Swift Laboratories Limited a North based Finished dosage player is upgrading the Manufacturing facility located at Jammu , J&K to EU-GMP/PICS standards in order to meet increased demand for its products in the Export Market . The facility which presently caters to the domestic market and soft regulated markets shall be able to generate additional revenues of Rs. 100 crores from the European and other regulated markets from FY 2029-30 . The plant is expected to be EU-GMP complaint and approved by early 2028. The total planned investment on the plant upgradation is around Rs. 45 crores (excluding investment in R&D for facility upgradation, product development and production registrations) The Jammu facility which presently caters to the all leading domestic Third parties manufacturing, Domestic market/soft regulated market was built in the year 2008 and is spread over 14,700 sq meters of the built up area. Plant has an installed capacity to manufacture Oral Solid Dosage ( OSD) and Ointments and is WHO-GMP and ISO 9001:12008 complaint . Post upgradation the facility shall be able to cater to the markets of Rest of the World. The facility shall supplement both the CDMO and the own branding business of the Company . The Company recently declared its Q1 financial results for the FY27. Operating Income of the Company grew 21.16% year-on-year to ₹186.08 crore, from ₹153.58 crore in Q1 FY26. Operating EBITDA improved 2.85 times year-on-year to ₹33.32 crore, from ₹8.66 crore in the corresponding quarter last year. Operating EBITDA Margin expanded sharply by 1,258 basis points year-on-year to 17.91%, from 5.33% in Q1 FY26. PAT, excluding exceptional items, stood at ₹24.68 crore, a 2.04 times year-on-year jump from ₹8.12 crore. PAT Margin improved by 827 basis points year-on-year to 13.26%, from 4.99% in the corresponding quarter of the previous year. FOR FURTHER INFO PLEASE CONTACT: Pardeep Verma VP-Corporate Affairs and Company Secretary +91-9814131627 investor@indswiftlabs.Com